MDT-AP-1270
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 45.96
- os_event
- false
- age_years
- 8
- sex
- M
- new_clusters
- C3
- umap1_2d
- 6.020845613
- umap2_2d
- 4.183106577
- umap1_3d
- 3.094109249
- umap2_3d
- -2.180469025
- umap3_3d
- -2.839466113
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.230
- HEME_METABOLISM+0.200
- MITOTIC_SPINDLE+0.180
- SPERMATOGENESIS+0.110
- P53_PATHWAY+0.090
- KRAS_SIGNALING_DN+0.080
- HEDGEHOG_SIGNALING+0.050
- PANCREAS_BETA_CELLS+0.050
- BILE_ACID_METABOLISM+0.030
- ESTROGEN_RESPONSE_EARLY+0.020
Top 10 suppressed
- MYC_TARGETS_V1-0.560
- INTERFERON_ALPHA_RESPONSE-0.460
- ALLOGRAFT_REJECTION-0.450
- OXIDATIVE_PHOSPHORYLATION-0.440
- ANGIOGENESIS-0.430
- E2F_TARGETS-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- ANDROGEN_RESPONSE-0.350
- INTERFERON_GAMMA_RESPONSE-0.340
- G2M_CHECKPOINT-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1279 | Med | Medulloblastoma | 0.891 |
| 2 | MDT-AP-0222 | Med | Medulloblastoma | 0.887 |
| 3 | MDT-AP-1405 | Med | Medulloblastoma | 0.885 |
| 4 | MDT-AP-1120 | Med | Medulloblastoma | 0.859 |
| 5 | MDT-AP-0847 | Med | Medulloblastoma | 0.859 |
| 6 | SRR11296800 | — | — | 0.856 |
| 7 | MDT-AP-1160 | Med | Medulloblastoma | 0.856 |
| 8 | MDT-AP-0376 | Med | Medulloblastoma | 0.855 |
| 9 | MDT-AP-1261 | Med | Medulloblastoma | 0.854 |
| 10 | MDT-AP-0394 | Med | Medulloblastoma | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.090 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.050 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.010 | Inavolisib | — uncovered |